Recombinant Human Prss22 protein

Prss22. also known as serine protease 22. is a member of the trypsin-like serine protease family characterized by a conserved catalytic triad (histidine, aspartate, and serine) essential for enzymatic activity. This protein is encoded by the PRSS22 gene in humans and is implicated in diverse physiological and pathological processes, including tissue homeostasis, immune regulation, and inflammation. Unlike many well-studied serine proteases, Prss22 remains relatively undercharacterized, though emerging research highlights its potential roles in skin barrier function, epithelial differentiation, and immune cell signaling. Studies suggest its involvement in processing extracellular matrix components or modulating cytokine activity, though specific substrates remain largely unidentified.

Recombinant Prss22 protein is produced via genetic engineering techniques, typically expressed in mammalian or insect cell systems to ensure proper post-translational modifications. Its production enables functional studies to dissect biochemical properties, substrate specificity, and interactions with inhibitors. Interest in recombinant Prss22 has grown due to its association with diseases such as atopic dermatitis, psoriasis, and certain cancers. For instance, dysregulated Prss22 expression has been observed in skin inflammation models and tumor microenvironments, suggesting therapeutic targeting potential. However, mechanistic insights into its regulatory pathways and physiological relevance remain limited, partly due to overlapping substrate specificities with other serine proteases and a lack of selective inhibitors. Current research focuses on elucidating its structure-function relationships, tissue-specific roles, and contributions to disease progression, positioning recombinant Prss22 as a valuable tool for both basic science and drug discovery.